Rusan Pharma Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Rusan Pharma Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $1.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Rusan Pharma Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $1.1M Trade | TransData Nexus

Rusan Pharma Limited

Indian Pharmaceutical Exporter · Analgesics & Antipyretics Specialist · $1.1M Total Trade · DGFT Verified

Rusan Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $1.1M across 5 products in 4 therapeutic categories. Based on 73 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Morphine ($545.4K), Fentanyl ($293.4K), Diazepam ($121.4K).

Rusan Pharma Limited — Export Portfolio & Destination Treemap

Rusan Pharma Limited pharmaceutical export portfolio — 5 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Rusan Pharma Limited? — Company Overview & Market Position

Rusan Pharma Limited, established on March 15, 1994, is a privately held Indian pharmaceutical company specializing in the production of finished pharmaceutical formulations. The company is registered under the Corporate Identification Number (CIN) U24230MH1994PLC077069 and is headquartered at Rusan House, 58-D, Government Industrial Estate, Charkop, Kandivali (West), Mumbai, Maharashtra, India.

As of the latest available data, Rusan Pharma Limited has an authorized capital of ₹50 million and a paid-up capital of ₹48.41 million. The company is classified as a public unlisted entity and operates in the manufacturing sector, focusing on pharmaceuticals and medicinal chemicals.

The company's product portfolio includes a range of dosage forms such as tablets, capsules, syrups, and injections, catering to various therapeutic areas. Rusan Pharma Limited has established a strong presence in both domestic and international markets, emphasizing quality and compliance with international standards.

What Does Rusan Pharma Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Morphine$545.4K 2

Product Portfolio — Top 5 by Export Value

Rusan Pharma Limited exports 5 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Morphine	Analgesics & Antipyretics	$545.4K	17	3.1%	3
2	Fentanyl	Analgesics & Antipyretics	$293.4K	19	7.8%	3
3	Diazepam	CNS & Psychiatric	$121.4K	4	1.6%	11
4	Glibenclamide	Advanced Diabetes Medications	$107.8K	3	0.3%	9
5	Nicotine	Other	$68.0K	30	0.5%	6

Rusan Pharma Limited exports 5 pharmaceutical products across 4 therapeutic categories with a total export value of $1.1M. The top category is Analgesics & Antipyretics (73.8% of portfolio), followed by CNS & Psychiatric (10.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Rusan Pharma Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Rusan Pharma Limited operates multiple manufacturing facilities across India, each designed to meet specific production requirements and regulatory standards.

The Kandla Unit I in Gujarat specializes in the production of tablets, general capsules, sachets, injectables (lyophilized and liquid vials), glass ampoules, and cream & ointment formulations. This facility has received approvals from regulatory bodies in Brazil, South Africa, Tanzania, Zimbabwe, the UAE, Kenya, Uganda, Russia, Kazakhstan, and holds State-GMP and WHO-CDSCO certifications.

The Kandla Unit II, also in Gujarat, focuses on the manufacturing of transdermal patches, with an annual capacity of 6 million units. It is approved by authorities in Brazil, Australia, the UAE, and holds State-GMP and WHO-CDSCO certifications.

The Dehradun facility in Uttarakhand produces tablets, general capsules, oral liquids (syrups), transdermal patches, glass vials, and prefilled syringes. This plant has approvals from Canada, Europe, Australia, Brazil, South Africa, Ukraine, Kenya, Uganda, Switzerland, the UAE, Vietnam, and holds State-GMP and WHO-CDSCO certifications.

Additionally, Rusan Pharma Limited has API manufacturing facilities in Ankleshwar, Gujarat, and Pithampur, Madhya Pradesh. The Ankleshwar facility has an annual production capacity of 33 KL (33 tons) and is approved by the USFDA, Canada, Europe, Japan, Brazil, State-GMP, and WHO-CDSCO. The Pithampur facility, inaugurated in November 2023 with an investment of approximately ₹300 crore, focuses on the production of active pharmaceutical ingredients (APIs) for addiction treatment and pain management products.

3Key Leadership

Rusan Pharma Limited's leadership comprises individuals with extensive experience in the pharmaceutical industry. The company's board of directors includes:

Navin Satyapal Saxena
Balasaheb Annasaheb Patil
Kunal Navin Saxena
Ajay Ramasaran Saxena
Sandeep Verma
Aakarsh Navin Saxena

These directors play pivotal roles in steering the company's strategic direction and ensuring compliance with regulatory standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Rusan Pharma Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Rusan Pharma Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities hold approvals from various regulatory bodies, facilitating market access in these regions.

In the United States, the Ankleshwar facility is approved by the USFDA, enabling Rusan Pharma Limited to supply products to the US market.

In Europe, the Dehradun facility has received approvals from European regulatory authorities, allowing the company to distribute its products across European countries.

The Australian market is accessible through approvals for the Kandla Unit II and Dehradun facilities, which are certified by the Therapeutic Goods Administration (TGA).

In Japan, the Ankleshwar facility holds approvals from Japanese regulatory authorities, facilitating market entry.

These regulatory approvals underscore Rusan Pharma Limited's commitment to maintaining high-quality standards and compliance with international regulations, thereby ensuring the safety and efficacy of its products in these markets.

2Emerging Markets

Rusan Pharma Limited has strategically expanded its footprint into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's manufacturing facilities have obtained approvals from various regulatory bodies in these regions, facilitating market access and distribution.

Rusan Pharma Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Rusan Pharma Limited's Ankleshwar facility in Gujarat holds approvals from the US Food and Drug Administration (FDA), enabling the company to supply pharmaceutical products to the United States market.

The facility's compliance with FDA regulations underscores Rusan Pharma Limited's commitment to maintaining high-quality standards and ensuring the safety and efficacy of its products for the US market.

2WHO & EU GMP

Rusan Pharma Limited's manufacturing facilities have obtained certifications from the World Health Organization (WHO) and the European Union Good Manufacturing Practice (EU GMP), reflecting the company's adherence to international quality standards.

These certifications are indicative of Rusan Pharma Limited's dedication to producing pharmaceutical products that meet global quality benchmarks, thereby ensuring the safety and efficacy of its offerings in international markets.

3CDSCO & Indian Regulatory

Rusan Pharma Limited's manufacturing facilities are approved by the Central Drugs Standard Control Organisation (CDSCO) and hold State-GMP certifications, ensuring compliance with Indian regulatory standards.

Rusan Pharma Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Rusan Pharma Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products in the analgesics, CNS & psychiatric, and advanced diabetes medications categories. The company's focus on de-addiction and pain management products differentiates it from competitors, allowing it to carve out a niche in these therapeutic areas.

While specific market share data for competitors is not available, Rusan Pharma Limited's strategic focus on specialized formulations positions it

TransData Nexus Research · DGFT export records, industry analysisMar 2026

Frequently Asked Questions — Rusan Pharma Limited

How many pharmaceutical products does Rusan Pharma Limited export from India?

Rusan Pharma Limited exports 5 pharmaceutical products across 4 therapeutic categories. The top exports are Morphine ($545.4K), Fentanyl ($293.4K), Diazepam ($121.4K), Glibenclamide ($107.8K), Nicotine ($68.0K). Total export value is $1.1M.

What is Rusan Pharma Limited's total pharmaceutical export value?

Rusan Pharma Limited's total pharmaceutical export value is $1.1M, based on 73 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Rusan Pharma Limited cover?

Rusan Pharma Limited exports across 4 therapeutic categories. The largest are Analgesics & Antipyretics (73.8%, 2 products), CNS & Psychiatric (10.7%, 1 products), Advanced Diabetes Medications (9.5%, 1 products).

Get Full Rusan Pharma Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.